Hyperhidrosis Market

Market Overview:

The 7 major hyperhidrosis markets reached a value of US$ 426.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 651.2 Million by 2034, exhibiting a growth rate (CAGR) of 3.92% during 2024-2034.

The hyperhidrosis market has been comprehensively analyzed in IMARC's new report titled "Hyperhidrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hyperhidrosis is a disorder of abnormally excessive sweating that’s usually not related to exercise or body temperature. It mainly occurs due to the overactivation of cholinergic receptors on eccrine glands. The sweating may impact the entire body or only affect certain regions, such as extremities, underarms, and face. Depending on the causative factor and disease extension, hyperhidrosis is classified as primary focal hyperhidrosis and secondary generalized hyperhidrosis. Primary focal hyperhidrosis refers to excessive sweating which is not caused by another medical condition or any medications, whereas secondary generalized hyperhidrosis occurs due to an underlying medical ailment or as a side effect of certain medications, such as pain relievers, antidepressants, hormonal medications, etc. Hyperhidrosis can result in emotional, social, psychological, and occupational impairment among patients. Individuals suffering from hyperhidrosis may experience itching, inflammation, body odor, paleness, discoloration, cracks or wrinkles in the skin, night sweats, maceration on the soles of the feet, residual marks on clothing from combinations of sweat, bacteria, and chemicals, etc. The diagnosis of this ailment requires a review of the patient’s health history and a thorough evaluation of underlying symptoms. The healthcare provider may also perform a starch-iodine test and a paper test to measure the amount of sweat the body produces.

The increasing cases of hereditary disorders, causing malfunction in the nerve signals that overstimulate sweat glands in the body, are primarily driving the hyperhidrosis market. Apart from this, the rising prevalence of several associated risk factors, such as anxiety, low blood sugar, menopause, obesity, certain drugs like anti-depressants and beta-blockers, etc., is also propelling the market growth. Moreover, the escalating utilization of anticholinergics, including glycopyrrolate, oxybutynin, propantheline, benztropine, etc., which block signals from nerves and reduce sweat production in patients, is creating a positive outlook for the market. In addition to this, the inflating usage of microwave thermolysis therapy to treat advanced disease conditions is also bolstering the market growth. This non-invasive technique delivers precisely controlled microwave energy to destroy the sweat glands and provides a long-term reduction in excessive sweating. Furthermore, numerous key players are making substantial investments in R&D activities to launch novel over-the-counter and economically feasible topical products for treating hyperhidrosis. This, in turn, is acting as another significant growth-inducing factor. Additionally, the widespread adoption of video-assisted thoracoscopic sympathectomy, which allows shorter operating time, early recovery, and improves patient outcomes, is expected to drive the hyperhidrosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the hyperhidrosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for hyperhidrosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hyperhidrosis market in any manner.

Recent Developments:

• In September 2023, Candesant Biomedical announced that Brella, the only 3-Minute SweatControl Patch, has won the 2023 Allure Best of Beauty Breakthrough Award. Brella is FDA-approved for treating excessive underarm sweating (primary axillary hyperhidrosis) in adults.

Key Highlights:

• Hyperhidrosis affects at least 176 million people globally.
• The prevalence of hyperhidrosis is approximately 15.3 million people in the US population.
• The prevalence rate is 2.1% among children and adolescents and people 65 years of age and beyond, with the largest rates occurring in the 18–39 age group (8.8%).
• Hyperhidrosis is widely defined into two types: primary hyperhidrosis and secondary hyperhidrosis, which can be further divided into focal or generalized.
• In India, hyperhidrosis affects about 2.5-3 percent of the population.

Drugs:

Onabotulinum toxin A is a natural, pure protein that operates by inhibiting the nerve signals that instruct sweat glands to activate. Botox injections for hyperhidrosis produce results in three to four days.

AT-5214 (dexmecamylamine) is the S-enantiomer of mecamylamine, which selectively inhibits the acetylcholine nicotinic receptor. AT-5214 is thought to block the sympathetic ganglion and reduce parasympathetic side effects.

Meditoxin is a Botulinum Toxin from the Clostridium botulinum family that is only available via prescription. It provides therapy results that last up to 6 months and are visible within 3 to 6 days of the injection process.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hyperhidrosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hyperhidrosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current hyperhidrosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the hyperhidrosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the hyperhidrosis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the hyperhidrosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of hyperhidrosis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hyperhidrosis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hyperhidrosis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with hyperhidrosis across the seven major markets?
• What is the size of the hyperhidrosis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of hyperhidrosis?
• What will be the growth rate of patients across the seven major markets?
   

Hyperhidrosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for hyperhidrosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hyperhidrosis market?
• What are the key regulatory events related to the hyperhidrosis market?
• What is the structure of clinical trial landscape by status related to the hyperhidrosis market?
• What is the structure of clinical trial landscape by phase related to the hyperhidrosis market?
• What is the structure of clinical trial landscape by route of administration related to the hyperhidrosis market?